The latest edition of From the Bench features creative cancer research, including making tumors seem like pig organs, starving cancer with fat, and more.
Disasters present a threat to cancer care, and understanding prostate cancer screening recommendations after President Joe Biden’s diagnosis.
At the AACR Annual Meeting 2025, researchers and patient advocates shared insights into the impact of NIH funding cuts on cancer research.
Learn how a Gleason score is calculated to help determine the aggressiveness of prostate cancer, and how it could influence a patient's treatment.
Research unveiled at the AACR Annual Meeting 2025 highlighted advances in blood-based liquid biopsy tests to help improve cancer care.
Study examines benefit of PARP inhibitors before surgery in BRCA-related breast cancer, and exercise improves sexual function after prostate cancer treatment.
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer.
The largest increases were found in breast, colorectal, endometrial, pancreatic, and kidney cancers. Early-onset cancers, or cancers diagnosed in individuals under the age of 50, are rising in the United States. While the exact...
The FDA has approved retifanlimab-dlwr, both alone and in combination with chemotherapy, for certain patients with anal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved retifanlimab-dlwr (Zynyz) for patients with...
The FDA has approved telisotuzumab vedotin-tllv for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More